McKesson earnings up next: Can revenue rebound after Q4 miss? By Investing.com

McKesson is set to release its fiscal first-quarter earnings, with investors closely watching for a rebound in revenue after a significant miss in the prior quarter. Analysts expect robust earnings and revenue growth, but the stock has experienced recent volatility due to concerns about direct-to-patient distribution and potential margin pressures from specialty pharmaceuticals and GLP-1 drugs. The upcoming earnings report will test whether McKesson's operational execution can overcome sector challenges and reassure investors about its market position.